Klaus-Michael Weltring

Klaus-Michael Weltring

Klaus-Michael Weltring

Managing Director at Nanobioanalytic Muenster, Member of Board at ETP Nanomedicine

Dr. Klaus-Michael Weltring is a molecular biologist by training with a PhD and a Habilitation degree from the University of Münster. Since 2001 he is the managing director of bioanalytik-muenster, a local network of researchers from different disciplines and SMEs, responsible for the development of the Münster region into a leading nanobioanalytic location at the European level.

Between 2003 and 2008 he was the deputy-coordinator of the Nano2Life Network of Excellence and leader of the “ELSA” Board in this network. He co-managed the Nanomedicine Round Table and the EuroNanoBio projects and participated in the NANOMED2020 project (FP7 CSA projects).

Since 2009 he is a member of the Executive Board of the ETP Nanomedicine leading the ELSA Advisory Group of this platform. Since March 2015 he is the chair of the German platform NanoBioMedicine. At the local level he is the Chief Scientific Officer of the Nano-Bioanalytik-Zentrum Münster (NBZ) and manages the Nano-Characterization-Lab Muenster (www.NCL-Muenster.de) interfacing 11 local companies, which develops new and certified methods for characterization of Nanomaterials in consumer products and biological systems.

Currently he is partner in the EU-projects ENATRANS and EU-NCL.

Read more about Klaus-Michael and his work here.

Abstract Title: Nanomedicine driving the new collaborative business model of smart and connected medical devices

Abstract: Nanotechnology is one of the crucial key enabling technologies to provide solutions for the three paradigm shifts we currently see in medicine, i) acute medicine vs. preventive medicine, ii) general drugs vs. personalised drugs, and iii) treatment of chronic diseases vs. cure of these diseases, because it provides the high resolution analytical tools to better understand the cause of diseases at the nanoscale where they originate and at the same time it creates new materials for earlier diagnosis and more targeted therapy. However, Integration of nanotechnology into biomedical applications will require new trans-disciplinary research concepts and new cross-industry healthcare value chains for Europe to get a share of the global nanomedicine market sector, which is growing rapidly. This will require new partnerships between researchers, SMEs, industry, clinicians, patients and authorities including regulators and funding agencies. A faithful partnership of these public and private stakeholders will not only provide new and better healthcare for European citizens, but also supports the aims of the Europe 2020 Strategy and Industry 2020 Initiative to stimulate sustainable growth and create jobs by improving the global competitiveness of the European medical industry and healthcare sector.